Exceptional scientists wanted

Present your work to the world.

Are you a representative of the upcoming generation of thought leaders in your field? Together we look forward to your application for the new Sartorius & *Science* Prize for Regenerative Medicine & Cell Therapy.

Apply now!

www.sartorius.com/sartorius-and-science-prize
Science Webinars help you keep pace with emerging scientific fields!

Stay informed about scientific breakthroughs and discoveries.
Gain insights into current research from top scientists.
Take the opportunity to ask questions during live broadcasts.
Get alerts about upcoming free webinars.

Sign up at: webinar.sciencemag.org/stayinformed
**New products**

**FFF Platform**
The Postnova AF2000 MultiFlow FFF Series is a modular-flow, field-flow fractionation (FFF) platform. It is based on the flow FFF principle, using a crossflow field as the driving force for the separation. The samples are separated by their dynamic diffusion on the basis of molar mass or particle size. The AF2000 can be run with different eluents at various temperature conditions, and is able to employ various channel dimensions and principles. The same system can run planar asymmetric flow FFF (AF4) channels or circular hollow-fiber flow FFF (HF5) channels, so it can be easily used for separation of a broad range of different samples in applications including biopharmaceuticals, food-agro-cosmetics, environmental, chemicals, and nanotechnology. The AF2000 is ideal for the characterization of proteins, antibodies, aggregates, vaccines, liposomes, nanoparticles, and natural or synthetic macromolecules. Because of its great flexibility, the AF2000 can be employed as a universal separator for many kinds of analyte systems and is also a secure investment for upcoming samples and future project demands.

**Postnova Analytics**
For info: 801-521-2004

**Drug Target Identification Platform**
Taxonomy3 is a novel, in silico platform technology that utilizes proprietary, groundbreaking mathematical algorithms to analyze complex genetic datasets, for the purpose of identifying and characterizing new drug target candidates. Taxonomy3 can identify previously unknown genetic linkages and interactions between genes and biological pathways in a broad range of diseases. This capability enables the discovery of targets that cause disease, rather than those that are simply associated with its symptoms, thereby providing the best starting point for drug discovery, biomarker identification, and patient stratification, and ultimately improving the chances of clinical success.

**C4X Discovery**
For info: +44-(0)-161-235-5085
www.c4xdiscovery.com/technology/taxonomy3.html

**Phenotypic Screening Platform**
PhoreMost has developed a next-generation phenotypic screening platform called SITESEEKER that can discern the best new targets for future therapy and crucially, how to drug them, which has the potential to significantly increase the diversity and affordability of novel therapeutics for cancer and other unmet diseases. Based on the company's core proprietary "protein-interference," or PROTEIni, technology, SITESEEKER systemically unmaps cryptic druggable sites across the entire human genome and directly links them to useful therapeutic functions in a live-cell context. Using this platform, PhoreMost is building a pipeline of novel drug discovery programs aimed at addressing a range of unmet diseases.

**PhoreMost**
For info: +44-(0)-1223-804-161
www.phoremost.com

**Microsatellite Instability Assay for Colorectal Cancer**
Bio-Rad's Droplet Digital PCR (ddPCR) Microsatellite Instability (MSI) RUO Assay is available for early-access customers. The assay can be completed in one day on a ddPCR-based platform to quantify the level of MSI present in colorectal tumors. Using either a blood or FFPE sample, the assay quantitatively identifies mutations in five loci that lead to identification of MSI status. Colorectal tumors that test positive for MSI-high are candidates for treatment with immune-checkpoint inhibitors. Bio-Rad's assay is simple, highly sensitive, and provides a standardized output that does not require a pathologist's interpretation. The test can use patient blood samples in the absence of tumor tissue and does not call for matched normal tissue or normal blood samples.

**Bio-Rad**
For info: 800-424-6723
www.bio-rad.com

**Bioreactor Vessel**
Sartorius Stedim Biotech offers a new vessel for its ambr 250 modular benchtop automated mini bioreactor system. The single-use vessel has been designed for therapeutic cell lines and offers the potential for accelerated process development of cell and gene therapy applications and scale-up into Current Good Manufacturing Practices (cGMP) single-use bioreactors and bags. The new unbaflled vessel design with a large, pitched-blade impeller has a working volume of 100 mL–250 mL and provides an environment for gentle agitation and mixing without sedimentation, allowing optimal growth of single-cell suspensions, cell aggregates, or adherent cells on microcarriers. In trials with leading regenerative medicine companies, the new mini bioreactor has shown better cell culture performance compared with less predictive spinner or T-flask models, enabling rapid process optimization and improved scalability to larger bioreactors.

**Sartorius Stedim Biotech**
For info: 631-254-4249
www.sartorius.com

**CAR-T Cells and Products**
AMS Biotechnology (AMSBIO) announces best-in-class CAR-T cells, engineered CAR-T target cells, peripheral blood mononuclear cells, cell media, and activation beads, in response to the rapid growth in research on the therapeutic uses of CAR-T cells. All AMSBIO CAR-T cell products are T cells produced from either a group of donors or from individual donors transduced with chimeric antigen receptor (CAR) lentivirus. These cells can target different tumor antigens such CD19, CD133, HER2, EGFR, VEGFR-2, or mesothelin that are highly overexpressed in tumors, and can express inducible caspase-9 or other suicide genes to trigger CAR-T cell killing for increased safety, should this application be proposed for future clinical trials. All AMSBIO CAR-T cell products can be validated for transduction efficiency, cell-killing activity, and real-time cytotoxicity activity, and include negative mock controls: lentivirus-transduced CAR-T cells, no single-chain fragment variable (ScFv)-transduced CAR-T cells, and nontransduced T cells.

**AMSBiotechnology**
For info: 800-987-0985
www.amsbio.com/car-t-cell-research.aspx

Electronically submit your new product description or product literature information! Go to www.sciencemag.org/about/new-products-section for more information.

Newly offered instrumentation, apparatus, and laboratory materials of interest to researchers in all disciplines in academic, industrial, and governmental organizations are featured in this space. Emphasis is given to purpose, chief characteristics, and availability of products and materials. Endorsement by Science or AAAS of any products or materials mentioned is not implied. Additional information may be obtained from the manufacturer or supplier.
The 2019 Member Survey is launching in the fall. Look in your inbox for a link. Your responses help us to better serve science, scientists, and the global community. Don’t miss your chance to tell us what’s most important to you!
Publish your research in *Science Signaling*

*Science Signaling* publishes the latest advances in regulatory biology relevant to physiology and disease, including insights into the basic mechanisms of intracellular signaling and intercellular regulation, host-microbe interactions, applied signaling for drug discovery and synthetic biology, and the development of novel analysis methods.

Submit your research today. Learn more at: [ScienceSignaling.org](http://ScienceSignaling.org)